TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00567580

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBRT
Description: 1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PBRT
Description: 1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBRT
Description: 1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PLNRT
Description: 1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA
Description: Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA
Description: Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
Study: NCT06150690

Intervention type: OTHER
Intervention: No intervention
Description: The participants did not receive any study-specific intervention

Intervention type: OTHER
Intervention: No intervention
Description: The participants did not receive any study-specific intervention

Intervention type: OTHER
Intervention: No intervention
Description: The participants did not receive any study-specific intervention
Study: NCT04423328

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: acupressure
Description: self-acupressure
Study: NCT02021526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
Study: NCT01924910

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 250,000 IU cholecalciferol as single, oral dose
Description: 250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04181307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-EHR module
Description: The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
Study: NCT01058746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive perioperative fluid management
Description: Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal perioperative fluid management
Description: Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
Study: NCT03336229

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Graduated walking programme, strengthening exercises and respiratory muscle training.
Study: NCT03182855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor Tetrasodium
Description: Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
Study: NCT04196621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High viscous artificial tears
Description: Instillation of one drop high viscous artificial tears

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low viscous artificial tears
Description: Instillation of one drop low viscous artificial tears
Study: NCT00133705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 5mg/day by mouth for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Capsule
Description: sugar pill
Study: NCT03320005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training group
Description: Resistive exercises for legs and arms
Study: NCT01765400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10 mg daily x 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg daily x 2 weeks
Study: NCT04033640

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor STANDARD G6PD Test
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count (CBC)
Description: In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
Study: NCT01651988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamina-Propofol Combination
Description: After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamina-Propofol Combination
Description: After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min
Study: NCT03973320

Intervention type: OTHER
Intervention: Chart Review
Description: This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
Study: NCT03378960

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole 20mg
Study: NCT04225767

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
Study: NCT01690533

Intervention type: DRUG
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Patients treated with Moxifloxacin in daily clinical practice
Study: NCT03514576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.3 MG/ML
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.3 MG/ML
Description: See arm description

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
Study: NCT02642757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUDIT brief intervention
Description: Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet on alcohol use
Description: Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pamphlet on alcohol use
Description: Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
Study: NCT02682056

Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedle patch
Description: The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravenous (IV) catheter
Description: The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lancet
Description: The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
Study: NCT04329884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled RFA treatment with COOLIEF* device
Description: Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular corticosteroid injection
Description: Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
Study: NCT02957838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C18:0
Description: Receives 24g of C18:0 in a low-fat banana milkshake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C18:0
Description: Receives 24g of C18:0 in a low-fat banana milkshake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mock
Description: Low fat banana milkshake without C18:0 supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mock
Description: Low fat banana milkshake without C18:0 supplement.
Study: NCT03314090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone Gels
Description: silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
Study: NCT03134040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives (Rebate)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives (Donation)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Study: NCT00569179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent System
Description: Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
Study: NCT01400711

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative care
Description: Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Nasogastric tube until bowel function, late oral eating, opioid analgesics.
Study: NCT02499614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
Study: NCT03747692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study group
Description: local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
Study: NCT00642291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
Study: NCT02970565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Play Intervention
Description: Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
Study: NCT00601367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin flexible dose
Description: Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site.
Study: NCT00893802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
Study: NCT00184925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy
Description: trachesotomy with subglottic drainage
Study: NCT01175122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H2N3 MO 2003/AA ca Vaccine
Description: 0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043
Study: NCT00184925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cannula with subglottic drainage
Study: NCT00901069

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine with rituximab, vincristine, and cyclophosphamide
Description: Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
Study: NCT02808039

Intervention type: OTHER
Intervention: Platelet reactivity testing
Description: assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
Study: NCT03618134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Radical Neck Dissection
Description: Undergo modified radical neck dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Radical Neck Dissection
Description: Undergo modified radical neck dissection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Undergo TORS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Undergo TORS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV